Budecort

Budecort

budesonide

Manufacturer:

AstraZeneca

Distributor:

AstraZeneca
Concise Prescribing Info
Contents
Budesonide
Indications/Uses
Turbuhaler: Bronchial asthma. Respules: Bronchial asthma which require maintenance w/ glucocorticosteroids for control of underlying airway inflammation. Croup (viral laryngotracheobronchitis or laryngitis subglottica) in infants & childn.
Dosage/Direction for Use
Turbuhaler Adult 200-800 mcg/day, divided into 2-4 inhalations. More severe cases Up to 1,600 mcg. Full dose may be given in 1 administration w/ daily doses up to 400 mcg. Childn ≥6 yr 100-800 mcg/day, divided into 2-4 inhalations. Full dose may be given in 1 administration w/ daily doses up to 400 mcg. Respules Bronchial asthma Individualized dosage. Administration can be once daily or bid. Once daily administration can be used for 250-1,000 mcg once daily. Adult & elderly Initially, 1,000-2,000 mcg daily. Maintenance: 500-4,000 mcg daily, may be further increased in very severe cases. Childn ≥6 mth 250-500 mcg daily. Maintenance: 250-2,000 mcg daily. Adult & ped Non-corticosteroid treated patient & patient well-controlled by inhaled glucocorticoids. Maintenance: 250-1,000 mcg once daily. Croup Child & infant 2 mg as a single dose or 1 mg in 2 divided doses separated by 30 min, can be repeated every 12-36 hr.
Contraindications
Special Precautions
Regular monitoring of growth is recommended in childn & adolescents receiving long-term treatment w/ corticosteroids. Concomitant use w/ ketoconazole & itraconazole. Pregnancy & lactation. Turbuhaler: Risk of candida infections in the oral cavity & throat; rinse mouth w/ water after each dose. Risk of impaired adrenal function in patients transferring from systemic to inhaled glucocorticosteroids. Patients who required high dose emergency corticosteroid therapy or prolonged treatment at the highest recommended dose of inhaled corticosteroids. Patients transferred from systemically acting corticosteroids to budesonide & in cases of suspected disturbance of pituitary-adrenocortical function; consider tests of hypothalamic-pituitary-adrenocortical function. Previous symptoms eg, muscle & joint pain may return during transfer from oral steroid therapy to budesonide; increased oral steroid dose may be necessary. Allergies eg, rhinitis & eczema previously controlled by systemic treatment may be revealed when systemic steroid treatment is replaced by budesonide. Respules: Not intended for rapid relief of acute episodes of asthma where an inhaled short-acting bronchodilator is required. Risk of impaired adrenal function in patients transferring from oral corticosteroids, those who required high dose emergency corticosteroid therapy or prolonged treatment at the highest recommended dose of inhaled corticosteroids. Feeling of being unwell eg, muscle & joint pain may occur during w/drawal phase. Allergies eg, rhinitis & eczema previously controlled by systemic treatment may be unmasked when steroid treatment is replaced by inhaled therapy. Reduced liver function.
Adverse Reactions
Mild irritation in the throat, candida infection in the oropharynx, hoarseness, coughing.
Drug Interactions
Increased systemic exposure w/ potent CYP3A4 inhibitors eg, ketoconazole & itraconazole.
ATC Classification
R03BA02 - budesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
Presentation/Packing
Form
Budecort respules 250 mcg/mL
Packing/Price
2 mL x 20 × 1's
Form
Budecort respules 500 mcg/mL
Packing/Price
2 mL x 20 × 1's
Form
Budecort turbuhaler 200 mcg/dose
Packing/Price
100 dose x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in